Clinical Trial

Nab-Sirolimus and Endocrine Therapy in Recurrent Low Grade Serous Ovarian Cancer (NARETO)

Name: Nab-Sirolimus and Endocrine Therapy in Recurrent Low Grade Serous Ovarian Cancer (NARETO) — clinical trial record (NCT06494150)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Active, Not Recruiting Phase 2

View on ClinicalTrials.gov →

Summary

This single arm phase II study proposes to evaluate the efficacy and safety of nab-sirolimus + endocrine therapy (Fulvestrant) in patients with recurrent low grade serous ovarian cancer (LGSOC).

Protocol Amendment History 1 change

critical Trial status changed: Recruiting → Active, Not Recruiting 2026-06-13

Trial Details

NCT Number	NCT06494150
Lead Sponsor	University of Oklahoma Collaborators: Aadi Bioscience, Inc.
Conditions	Low Grade Ovarian Serous Adenocarcinoma
Enrollment	37 participants
Start Date	2024-12-26
Primary Completion	2027-08 (estimated)
Study Completion	2029-09 (estimated)
Updated on ClinicalTrials.gov	2026-06-12